0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV-79.08%PremiumDec 20, 2024Expiry Date3.78Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.27Leverage Ratio--Theta--Rho--Eff Leverage--Vega
PepGen Stock Discussion
Positive
▪️PGN-EDO51 achieved mean exon skipping levels of 2.15% after three months at 5 mg/kg dose
▪️Mean muscle-adjusted dystrophin level increased by 0.70% from baseline
▪️Mean absolute dystrophin level increased by 0.26% from baseline
▪️The 5 mg/kg dose was well-tolerated with no discontinu...
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$